Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aurinia Pharmaceuticals ( (AUPH) ) has provided an announcement.
Aurinia Pharmaceuticals announced that new data on LUPKYNIS (voclosporin) will be presented at the American College of Rheumatology Convergence and the American Society of Nephrology Kidney Week 2025. These presentations, in collaboration with independent investigators, will highlight real-world effectiveness, usage in pediatric patients, and the drug’s distribution and clearance. The findings aim to enhance the medical community’s understanding of voclosporin’s role in treating lupus nephritis, reinforcing Aurinia’s commitment to advancing patient care.
The most recent analyst rating on (AUPH) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals receives a strong overall score driven by its robust financial performance and positive earnings call. The company’s revenue growth, profitability improvements, and strategic guidance upgrades are significant strengths. However, technical analysis indicates potential short-term weakness, and the valuation suggests the stock may be overvalued. The decrease in cash due to share repurchases is a minor concern.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing therapies for autoimmune diseases with significant unmet medical needs. The company introduced LUPKYNIS (voclosporin) in January 2021, the first FDA-approved oral therapy for treating adult patients with active lupus nephritis. Aurinia is also working on aritinercept (AUR200), a dual inhibitor of B cell-activating factor and a proliferation-inducing ligand for potential autoimmune disease treatments.
Average Trading Volume: 2,026,006
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.46B
Find detailed analytics on AUPH stock on TipRanks’ Stock Analysis page.